



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q90923

Tasuku HONJO, et al.

Appln. No.: 10/553,406

Group Art Unit: Not yet assigned

Confirmation No.: Not yet assigned

Examiner: Not yet assigned

Filed: October 17, 2005

For:

A SCREENING METHOD OF A SUBSTANCE FOR THERAPY OF CARDIAC DISEASE AND A PHARMACEUTICAL COMPOSTION FOR THERAPY OF

CARDIAC DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/553,406

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents, together with an

English-language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 32,197

Mark Boland

Much Boland

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 29, 2006

2

Substitute for Form 1449 A & B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/553,406			
Confirmation Number	Not yet assigned			
Filing Date	October 17, 2005			
First Named Inventor	Tasuku HONJO			
Art Unit	Not yet assigned			
Examiner Name	Not yet assigned			
Attorney Docket Number	Q90923			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date		
		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US 2002/0127602	A1	09/12/2002	Shi et al.	
		US			1-2	
		US				
		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		wo	96/10076	A1	04/04/1996		English
		wo	00/54770	A1	09/21/2000		English
		WO	94/27156	A1	11/24/1994		English
		WO	03/006950	A2	01/23/2003		English
		wo	02/39813	Al	05/23/2002		Partial abstract

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		XP-000647600 - G. Wallukat et al., "Removal of autoantibodies in dilated cardiomyopathy by			
		immunoadsorption" (1996), International Journal of Cardiology, Vol. 54, No. 2, pp. 191-195	l		
		XP-002376772 - Taku Okazaki et al., "Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice" (2003), Nature Medicine, Vol. 9, No. 12, pp. 1477-1483			
		XP-002376773 - Alida L.P. et al., "Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance" (2002), The European Journal of Heart Failure, Vol. 4, No. 4, pp. 411-417			
		XP-002377071 - Hiroyuki Nishimura et al., "Autoimmune Dilated Cardiomyopathy in PD-1 Receptor- Deficient Mice" (2001), SCIENCE, Vol. 291, No. 5502, pp. 319-322			
		Partial European Search Report dated May 12, 2006			

Examiner Signature Date Considered				
	Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.